Skip to search boxSkip to navigationSkip to main content

MicroRNA-155 deficiency leads to decreased atherosclerosis, increased white adipose tissue obesity, and non-alcoholic fatty liver disease a novel mouse model of obesity paradox

  • Anthony Virtue
    ,
  • Candice Johnson
    ,
  • Jahaira Lopez-Pastraña
    ,
  • Ying Shao
    ,
  • Hangfei Fu
    ,
  • Xinyuan Li
*Corresponding author for this work
  • Temple University
    ,
  • Monell Chemical Senses Center
    ,
Scholary Output:
Contribution to journal
Article
Peer-review

Open access

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

Obesity paradox (OP) describes a widely observed clinical finding of improved cardiovascular fitness and survival in some overweight or obese patients. The molecular mechanisms underlying OP remain enigmatic partly due to a lack of animal models mirroring OP in patients. Using apolipoprotein E knock-out (apoE-/-) mice on a high fat (HF) diet as an atherosclerotic obesity model, we demonstrated 1) microRNA-155 (miRNA-155, miR-155) is significantly up-regulated in the aortas of apoE-/- mice, and miR-155 deficiency in apoE-/- mice inhibits atherosclerosis; 2) apoE-/-/miR-155-/- (double knockout (DKO)) mice show HF diet-induced obesity, adipocyte hypertrophy, and present with non-alcoholic fatty liver disease; 3) DKO mice demonstrate HF diet-induced elevations of plasma leptin, resistin, fed-state and fasting insulin and increased expression of adipogenic transcription factors but lack glucose intolerance and insulin resistance. Our results are the first to present an OP model using DKO mice with features of decreased atherosclerosis, increased obesity, and non-alcoholic fatty liver disease. Our findings suggest the mechanistic role of reduced miR-155 expression in OP and present a new OP working model based on a single miRNA deficiency in diet-induced obese atherogenic mice. Furthermore, our results serve as a breakthrough in understanding the potential mechanism underlying OP and provide a new biomarker and novel therapeutic target for OP-related metabolic diseases.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 1267-1287 (21 pages)

Journal (Volume, Issue Number)

Journal of Biological Chemistry (Volume 292, Issue 4)

Publication milestones

  • Published - 01/27/2017

Publication status

Published - 01/27/2017

ISSN

0021-9258

Publication IDs

  • Scopus: 85020629650
  • PubMed: 27856635

Publication metrics

Metrics

SciVal
FWCI
2.86
SciVal
Author count
16
SciVal
citations
50
SciVal
Paper percentile
97
SciVal
Top percentile
5
Scopus
citations
Fractional count
1
Fractional count
0.06
Fractional count
15
Fractional count
0.94
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
91
Captures
102

Funding Details

This work was supported by National Institutes of Health Grants R01 HL108910-01, R01 HL116917-01, and R01 HL131460-1 (to X.-F. Y. and H. W.). This work was also supported by American Heart Association predoctoral fellowship 12PRE11640013 (A. V.). The authors declare that they have no conflicts of interest with the contents of this article. This content is solely the responsibility of the authors and does not necessarily represent the official views of National Institutes of Health.
FundersFunding numbers
NIH
R01 HL131460-1, R01 HL108910-01, R01 HL116917-01
NIDDK
R01DK104116
AHA
12PRE11640013